Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering
Bambusa Therapeutics priced its upsized IPO at 10,555,555 shares and $16.00 per share, for expected gross proceeds of $168,888,880 before underwriting discounts and expenses. Underwriters hold a 30-day option on up to 1,583,333 additional shares. Shares are expected to begin trading on Nasdaq under BBTX on October 30, 2026, with closing on November 2, 2026. BofA Securities, Evercore ISI, UBS Investment Bank and Cantor are joint book-running managers.
Key figures
- Deal Value Usd
- 168888880
- Offering Price
- 16
- Shares Offered
- 10555555
- Option duration days
- 30
- Underwriters option shares
- 1583333
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.